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Abstract The BIG 1-98 trial is a large, randomized,
independently conducted clinical trial designed to compare
the efﬁcacy of upfront letrozole versus tamoxifen mono-
therapy and to compare sequential or up-front use of
letrozole and/or tamoxifen as an early adjuvant therapy for
patients with early breast cancer. We report on the results
from the primary core analysis of the BIG 1-98 trial of
8,010 patients, which compares monotherapy with letroz-
ole versus tamoxifen. This pre-planned core analysis
allowed the use of patient data from the monotherapy arms
of letrozole and tamoxifen and from the sequential
arms prior to the drug switch point. Patients randomized to
letrozole had a 19% improved disease-free survival (hazard
ratio [HR] = 0.81; P = 0.003), due especially to reduced
distant metastases (HR = 0.73; P = 0.001). A 14% risk
reduction of fatal events in favor of letrozole was also
observed (P = NS). The results from the monotherapy
arms alone conﬁrmed the ﬁndings from the primary core
analysis. Based on the results from this trial, the aromatase
inhibitor letrozole (Femara
1) is currently recommended as
a part of standard adjuvant therapy for postmenopausal
women with endocrine-responsive breast cancer and has
recently been approved in the early adjuvant setting in both
Europe and the United States. A subsequent analysis after
additional follow-up will address the question of mono-
therapy versus sequential therapy.
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Introduction and rationale
During the last century the management of primary breast
cancer has evolved from gross surgical intervention to a
sophisticated approach involving surgical, radiotherapeu-
tic, hormonal, chemotherapeutic, and targeted biologic
strategies. Currently, pharmacologic treatment is tailored
according to disease and patient characteristics, including
tumor size, histologic grade, lymph-node involvement,
hormone receptor (HR) status, and human epidermal
growth factor receptor-2 (HER2) overexpression. The
beneﬁts from adjuvant chemotherapy, adjuvant hormonal
therapy, and adjuvant therapy with trastuzumab have been
well-established [1, 2].
Patients with early breast cancer presenting with estro-
gen receptor (ER)-positive and/or progesterone receptor
(PgR)-positive tumors typically receive adjuvant hormonal
therapy. Adjuvant therapy with tamoxifen, a selective
estrogen receptor modulator (SERM), signiﬁcantly reduces
the risk of breast cancer recurrence [1]; the Early Breast
Cancer Trialists Collaborative Group reported that 5 years
of tamoxifen reduces the annual breast cancer death rate by
31% and is signiﬁcantly more effective than just 1–2 years
of tamoxifen in ER-positive breast cancer [1]. However,
intrinsic estrogenic activity [3–5] and increased risk of
endometrial cancer [6] and thromboembolism [7, 8] have
emerged as disadvantages when using tamoxifen. Based
on current published data, extending the course of adju-
vant tamoxifen beyond 5 years is not beneﬁcial [9] despite
the persistent risk of relapse in patients with HR+ breast
cancer [10].
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third-generation aromatase inhibitors (AIs) have shown
superior or equivalent efﬁcacy compared with tamoxifen
[11–15]. Letrozole demonstrated signiﬁcant superiority
in time to progression and overall response rate [12] and, in
addition, an early survival beneﬁt [11]. This indicates that a
subset of the breast tumors is inherently less sensitive to
tamoxifen [16] and that resistance to tamoxifen is acquired
more quickly [17]. This superiority of letrozole over
tamoxifen in the advanced setting led to the hypothesis that
this AI may also be superior to tamoxifen when adminis-
tered in the adjuvant setting.
The Breast International Group (BIG) 1-98 was
designed, coordinated, analyzed, and reported by an inde-
pendent academic group and currently is the largest
ongoing adjuvant trial in breast cancer investigating the
role of an AI. This review summarizes the design and
results from the primary core analysis of the BIG 1-98 trial,
which compared monotherapy with letrozole to mono-
therapy with tamoxifen and identiﬁed letrozole as a better
alternative to tamoxifen in this setting. It also summarizes
some of the additional published research using the BIG
1-98 database.
Trial design and patients
BIG 1-98 was a randomized, phase III, double-blind trial
with two randomization options: two-arms (A or B) and
four-arms (A, B, C or D) (see Fig. 1) for women with
operable invasive HR+ (ER+ and/or PgR+) breast cancer.
The treatment arms were: (A) initial therapy with tamox-
ifen for 5 years, (B) initial therapy with letrozole for
5 years, (C) initial therapy with tamoxifen for 2 years
followed by letrozole for 3 years, or (D) initial therapy
with letrozole for 2 years followed by tamoxifen for
3 years. The doses administered were 2.5 mg/day of
letrozole and 20 mg/day of tamoxifen.
Between March 1998 and March 2000, 1,835 women
were randomly assigned to arms A or B, and between April
1999 and May 2003 a further 6,193 were assigned to arms
A, B, C, or D. The primary core analysis compared treat-
ment effects of patients randomized to receive letrozole
initially (arms B and D) and those assigned to receive
tamoxifen initially (arm A and C). In the sequential treat-
ment groups (arms C and D), only events that occurred up
to 30 days after switching treatments were included in the
analysis. In total, 8,010 patients were included in the pri-
mary core analysis: 4,003 in the initial letrozole group
(arms B and D) and 4,007 in the initial tamoxifen group
(arms A and C) (see Fig. 2). Patient characteristics were
similar in the two treatment groups. Overall, the trial
included 41.3% node-positive and 57.3% node-negative
women, while 1.4% had unknown nodal status. Positive
HR status was an eligibility criterion. The majority of
patients (63.1%) had both ER+ and PgR+ tumors. A total
of 25.3% of women received adjuvant or neoadjuvant
chemotherapy.
End points
The primary end point of the trial was disease-free survival
(DFS), deﬁned as the time from randomization to ﬁrst
occurrence of: invasive recurrence in ipsilateral breast,
chest wall, regional site (internal mammary/axilla), or
distant site (including ipsilateral supraclavicular); contra-
lateral breast cancer (invasive); second malignancy
(non-breast); or death without prior cancer event. Protocol-
speciﬁed secondary end points in the BIG 1-98 trial were:
overall survival (OS), deﬁned as time from randomization
to death from any cause; systemic DFS, deﬁned as time
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Fig. 2 CONSORT (Consolidated Standards of Reporting Trials)
ﬂowchart of the BIG 1-98 trial. The primary core analysis includes all
8,010 assessable patients, but events and follow-up in the sequential
treatment groups (L ? T and T ? L) are truncated at 30 days after
switching to the other treatment. L denotes letrozole and T tamoxifen.
Reprinted from [18, Supplementary Appendix]
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123from randomization to distant recurrence; second non-
breast malignancy or death from any cause (ignoring local
and contralateral-breast events); and safety. Three addi-
tional end points were deﬁned in the statistical analysis
plan: (1) DFS excluding second, non-breast malignancies;
(2) time to recurrence, deﬁned as time from randomization
to ﬁrst breast cancer recurrence (excluding second, non-
breast cancers and censoring data on patients who died
without a prior cancer event); and (3) time to distant
recurrence, deﬁned as the time from randomization to the
ﬁrst breast cancer recurrence at a distant site.
Efﬁcacy analyses
Primary, secondary, and additional end points
At 25.8 months of follow-up, letrozole improved DFS by
19% (P = 0.003). The cumulative incidence of breast
cancer relapse was signiﬁcantly reduced with letrozole
compared with tamoxifen (see Fig. 3). The difference was
evident from 1 year after randomization and at 5 years was
10.3% in the letrozole group compared with 13.6% in the
tamoxifen group (P\0.001). In addition, letrozole sig-
niﬁcantly improved systemic DFS compared with
tamoxifen (hazard ratio 0.83; 95% CI 0.72–0.97). There
was signiﬁcant improvement with letrozole compared with
tamoxifen for the additional end point of DFS excluding
second non-breast cancers (hazard ratio 0.79; 95% CI 0.68–
0.92). Letrozole was particularly effective in decreasing the
risk of distant recurrence by 27% compared with tamoxifen
(hazard ratio 0.73; 95% CI 0.60–0.88; P = 0.001) (see
Fig. 4). A non-signiﬁcant 14% improvement in OS was
observed in patients receiving letrozole. Thus, 166 deaths
(4.1%) were observed in the letrozole group compared with
192 deaths (4.8%) in the tamoxifen group.
Subgroup analyses
Prospectively planned subgroup analyses, using the Cox pro-
portional-hazards model, for primary, secondary, and
additional end points are summarized in Fig. 4. Subgroup
analysis showed that the beneﬁcial effect of letrozole on DFS
was seen in ER+ tumors irrespective of PgR receptor status or
patient age [18]. The role of ER and PgR in trials comparing
AIs with tamoxifen remains an area of continued research [19,
20]. To explore this further, a central assessment of ER, PgR,
and HER2 was recently completed for 6,500 patients in BIG
1-98. Results from the ﬁrst 3,533 patients on the two mono-
therapy arms with ER+ tumors (by central assessment) and
centrally assessed PgR and HER2 conﬁrmed the results
reportedabovefromthelocalassessmentofreceptorstatus[18,
21], indicating that PgR status in ER+ tumors does not predict
responsiveness to letrozole when compared with tamoxifen.
The small group of patients with HER2 overexpression/
ampliﬁcationin the tumorhad a higher rate ofrecurrence with
bothtreatments,butthesuperiorityofletrozoleovertamoxifen
was similar irrespective of HER2 status [21].
For the primary end point of DFS, the relative risk
reductions for letrozole compared with tamoxifen were
29% in patients with node-positive tumors (hazard ratio
0.71, 95% CI 0.59–0.85), 24% in patients with tumors
[2 cm (hazard ratio 0.76, 95% CI 0.63–0.92), and 30% in
patients with prior chemotherapy (hazard ratio 0.70, 95%
CI 0.54–0.92). An additional logistic regression analysis of
BIG 1-98 was performed to retrospectively identify clinical
and pathological factors predictive of early breast cancer
recurrence [22]. The ﬁnal model, based on 5,980 patients
from the four-arm option and 212 events, identiﬁed the
following signiﬁcant factors: tumor size (P\0.001), ER/
PgR status (P\0.001), node positivity (P\0.001), and
tumor grade (P\0.001). There was a signiﬁcant interac-
tion between node positivity and treatment (P = 0.003).
Patients with the greatest risk of recurrence had ‡4 positive
nodes, tumors ‡5 cm, ER+/PgR– tumors, and grade 3
tumors. The increase in risk associated with increased node
positivity was greater for patients randomized to tamoxifen
than to letrozole [22].
Letrozole-only versus tamoxifen-only arms
The superiority of letrozole was conﬁrmed in a protocol-
deﬁned supplementary analysis, which was restricted to the
4,922 patients randomized to the monotherapy tamoxifen
or letrozole arms. At a median follow-up of 51 months,
letrozole provided a signiﬁcant beneﬁt for the end points
DFS (P = 0.007), DFS excluding secondary malignancy
(P = 0.01), time to recurrence (P = 0.004), and time to
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Fig. 3 Cumulative incidence of a breast cancer relapse in the BIG 1-
98 trial. Reprinted from [18] with permission from the Massachusetts
Medical Society
Breast Cancer Res Treat (2007) 105:55–66 57
123Safety
All adverse events were graded according to the Common
Toxicity Criteria of the National Cancer Institute (version
2). Predeﬁned adverse events were speciﬁcally asked and
documented at each study visit. Furthermore, the IBCSG
Coordinating Center conducted a medical review (review-
ers were blinded to randomization) of all grade 3–5
cardiovascular events and other grade 3–5 adverse events
that were considered clinically relevant but whose cause
was unclear, and all deaths of women in whom there was
no prior cancer-related event. The results of BIG 1-98
showed that letrozole was well-tolerated and had a safety
proﬁle different from tamoxifen (see Table 2)[ 18]. A more
detailed analysis of cardiovascular side effects, including
baseline risk factors and cholesterol values over time, has
recently been presented [24].
Tamoxifen compared with letrozole was associated with
an increased risk of thromboembolism, vaginal bleeding,
and more endometrial biopsies (9.1% vs. 2.3%, respec-
tively; P\0.001), with a higher incidence of invasive
endometrial cancers (0.3% vs. 0.1%, respectively;
Fig. 4 Cox proportional-
hazards model of data from the
BIG 1-98 trial. The size of the
boxes is inversely proportional
to the standard error of the
hazard ratio. The dashed
vertical shows the hazard-ratio
estimate for the overall analysis
of the primary study end point
(disease-free survival).
Reprinted from [18] with
permission from the
Massachusetts Medical Society
Table 1 Efﬁcacy end points in patients randomized to treatment with letrozole (n = 2,463) or tamoxifen (n = 2,459) for 5 years in the BIG 1-98
trial [23]
End point Events Hazard ratio 95% CI P-value
Let Tam
DFS (primary protocol deﬁnition) 352 418 0.82 0.71–0.95 0.007
Overall survival 194 211 0.91 0.75–1.11 0.35
Systemic DFS 331 374 0.87 0.75–1.01 0.07
DFS (ignoring second non-breast cancer) 307 364 0.83 0.71–0.96 0.01
Time to recurrence 231 291 0.78 0.65–0.92 0.004
Time to distant recurrence 193 234 0.81 0.67–0.98 0.03
DFS disease-free survival, Let letrozole, Tam tamoxifen, CI conﬁdence interval
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123P = 0.18). In addition, tamoxifen was associated with a
higher incidence of hot ﬂushes (38.0% vs. 33.5%, respec-
tively; P\0.001) and night sweats (16.2% vs. 13.9%;
respectively; P = 0.004).
There was a higher incidence of arthralgia and skeletal
events with letrozole compared with tamoxifen, including a
higher rate of fractures (5.7% vs. 4.0%, respectively;
P\0.001) and a shorter time to ﬁrst fracture.
Hypercholesterolemia was among the adverse events
listed on the case-report forms and was graded at each
study visit during treatment [18]. A total of 43.6% of
letrozole-treated and 19.2% of patients in the tamoxifen
group had hypercholesterolemia, reported at least once
during treatment [18]. Nevertheless, more than 80% of
reported hypercholesterolemia was grade 1, and thus of
uncertain clinical signiﬁcance. In addition, serum total
cholesterol values remained stable throughout the trial in
the letrozole arm but decreased in the tamoxifen arm by
approximately 13%, which is consistent with the known
lipid-lowering effect of tamoxifen [25]. Thus, median
changes in cholesterol values from baseline were 0, 0, and
–1.8% at 6, 12, and 24 months in the letrozole group and
–12.0, –13.5, and –14.1% in the tamoxifen group.
The overall incidence of cardiovascular events was
similar for the letrozole and tamoxifen groups. Although
there were higher incidences of grade 3–5 cardiac events
and cardiac failure in the letrozole arm, the incidences were
low in both groups (2.1% vs. 1.1%; P\0.001 and 0.8% vs.
0.4%, P = 0.01, respectively) in this older patient popula-
tion at competing risk for cardiovascular events [18].
Discussion
Clinical implications of BIG 1-98
The results of the primary core analysis [18], which
included all available data from patients randomly assigned
to the monotherapy arms and data from the sequential
therapy arms censored at the time of the therapy switch, as
well as the results from a recently published analysis lim-
ited to patients randomly assigned to the continuous
therapy arms [23], demonstrate a signiﬁcant beneﬁt of
letrozole over tamoxifen. Letrozole is at least as well-
tolerated as tamoxifen, offering patients and physicians a
true alternative. However, bone metabolism is differently
affected by letrozole and tamoxifen. Patients receiving AIs
are at increased risk for bone loss and osteoporosis and
should therefore receive appropriate monitoring and med-
ical intervention as part of daily practice.
As a result of the ﬁndings from BIG 1-98, letrozole was
approved both in Europe and the United States as an early
adjuvant treatment for postmenopausal women with HR+
breast cancer. The 2007 St. Gallen international consensus
guidelines [26] and updated National Comprehensive
Cancer Network (NCCN) guidelines [27] recommend
letrozole as an option for adjuvant treatment of early breast
cancer. In the 2007 St. Gallen Guidelines, use of an AI is
considered as an alternative to tamoxifen for postmeno-
pausal women with low-, intermediate-, or high-risk tumors
that are classiﬁed as endocrine-responsive or endocrine
response uncertain [26]. Similarly, in the NCCN guide-
lines, letrozole is a recommended adjuvant hormonal
therapy for all postmenopausal women with hormone-
responsive tumors, regardless of HER2 status [27]. The
current guidelines do not recommend one AI over another
but emphasize that treatment should be selected on the
basis of clinical trial evidence in speciﬁc settings [27], nor
do the guidelines provide recommendations as concerns the
optimal use of the AIs as upfront monotherapy or
sequenced with tamoxifen.
Results from the Arimidex, Tamoxifen, Alone or in
Combination (ATAC) trial provided evidence for superior
DFS with anastrozole versus tamoxifen used as initial
adjuvant hormonal therapy in postmenopausal women with
HR+ breast cancer [28, 29]. At a median follow-up of
Table 2 Cardiovascular adverse events and signiﬁcant other adverse events among patients included in the BIG 1-98 safety analysis [18]
Adverse event Incidence of any grade (%) P-value
Letrozole (n = 3,975) Tamoxifen (n = 3,988)
Cerebrovascular accident or transient ischemic attack 1.0 1.0 0.91
Thromboembolic event 1.5 3.5 \0.001
Cardiac event 4.1 3.8 0.61
Other cardiovascular event 0.5 0.2 0.04
Vaginal bleeding 3.3 6.6 \0.001
Hot ﬂashes 33.5 38.0 \0.001
Night sweats 13.9 16.2 0.004
Fracture 5.7 4.0 \0.001
Arthralgia 20.3 12.3 \0.001
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12368 months, no survival advantage has been observed in the
ATAC trial, and it remains an open question whether the
DFS advantage observed in AI trials will translate into an
OS advantage.
Both letrozole and anastrozole have demonstrated
superiority over tamoxifen as initial adjuvant therapy [18,
28], but a direct comparison of letrozole with anastrozole
awaits the results of a randomized head-to-head trial
(Femara Anastrozole Clinical Evaluation [FACE]) [30, 31].
The adjuvant FACE trial compares upfront therapy with
letrozole 2.5 mg with anastrozole 1 mg daily for up to
5 years in postmenopausal, HR+, node-positive breast
cancer patients. In addition, recruitment of a direct com-
parison of anastrozole and exemestane (MA.27) has been
completed recently.
Other trials demonstrated better disease control when an
AI was given after 2–3 years of adjuvant tamoxifen [32],
but so far, no trial has reported on a regimen of an AI given
2–3 years before tamoxifen. Initial treatment with the ‘‘gold
standard’’ tamoxifen followed by an AI may be a logical
long-term strategy because of the lack of complete cross-
resistance between these hormonal strategies. On the other
hand, the greater anti-estrogenic potency and higher anti-
tumor activity of AIs over tamoxifen, as demonstrated in
preclinical models and randomized clinical trials [12, 17,
33, 34], may suggest that it is preferable to use an AI upfront
to avoid early relapses that may occur while on tamoxifen
therapy. Thus, the key question, ‘‘should AIs be given as
initial therapy or used sequentially after tamoxifen?’’ is as
yet unanswered. Physicians often extrapolate data from
switch trials, e.g., the Intergroup Exemestane Study [35, 36]
or the MA.17 trial [33, 37] to sequential trials (e.g., BIG
1-98, Austrian Breast and Colorectal Cancer Study Group
[ABCSG] 8 [38]). In these sequential trials, events are
included in the analysis from treatment start and not from
point of switch after 2–3 years of tamoxifen. Sequential and
switch trials investigate obviously the same intervention but
are conducted in different patient groups, thus, results are
expected to be different and are different indeed.
Best use of AIs remains an open question, at least until
results of BIG 1-98 from the sequential use of letrozole and
tamoxifen, in comparison with continuous monotherapy, as
well as from the Tamoxifen and Exemestane Adjuvant
Multicenter trial investigating exemestane monotherapy
versus tamoxifen followed by exemestane [39] and from an
updated analysis of ABCSG-8, become available.
Conclusions
BIG 1-98 has shown that the AI letrozole results in better
disease control than tamoxifen when given as initial
endocrine therapy for postmenopausal women with
hormone-responsive early breast cancer. Letrozole signiﬁ-
cantly reduced the risk of recurrence and of distant
recurrence and has a reasonable safety proﬁle [18]. The
comparison between the monotherapy and the sequential
treatment arms within the BIG 1-98 trial are eagerly
awaited and are expected to have an important impact on
the management of breast cancer.
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